US2024025860A1PendingUtilityA1
Sars-cov-2 inhibitors for treating coronavirus infections
Est. expiryNov 2, 2041(~15.3 yrs left)· nominal 20-yr term from priority
C12N 2770/20022C07K 14/005C07D 493/08C07D 417/14C07D 417/12C07D 413/12C07D 405/14C07D 405/12C07D 401/12C07D 261/08C07D 239/30C07D 239/26C07D 213/85C07D 213/64C07D 213/61C07B 59/002A61K 31/506A61K 31/505A61K 31/4433A61K 31/4412A61K 31/44A61K 31/42C07D 233/96A61P 31/14C07D 403/12C07D 213/56C07B 2200/05
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.
Claims
exact text as granted — not AI-modified1 .- 62 . (canceled)
63 . A method of treating or preventing a coronavirus infection in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising (i) a compound of Formula (Ia), or a pharmaceutically acceptable salt or stereoisomer thereof:
wherein:
R 1 is fluoro and R 2 is chloro;
L is —(CR 4 R 4 ) p —;
each R 4 is independently hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, or C 1 -C 6 heteroalkyl;
p is 0;
R 5 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, or C 1 -C 6 heteroalkyl;
R 7 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, or C 1 -C 6 heteroalkyl; and
and
(ii) a pharmaceutically acceptable excipient.
64 . The method of claim 63 , wherein R 5 is C 1 -C 6 alkyl.
65 . The method of claim 63 , wherein R 5 is methyl.
66 . The method of claim 63 , wherein R 7 is hydrogen.
67 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt or stereoisomer thereof.
68 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
69 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
70 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
71 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
72 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
73 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
74 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
75 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
76 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
77 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
78 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
79 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
80 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
81 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
82 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
83 . The method of claim 63 , wherein the compound of Formula (Ia) is selected from the group consisting ofJoin the waitlist — get patent alerts
Track US2024025860A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.